Northwire Canada EditionThursday, August 6, 2026

Sign in Subscribe

ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2% ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2%

M&A / Property

Optimind cancels Monjin acquisition

By The Northwire Desk — AI Analysis Sep 05, 2025 · 04:30 OMND · 0.005 Optimind Pharma Corp

OMND · Price

Executive Summary

Optimind Pharma Corp. has mutually terminated the previously announced non-binding letter of intent (LOI) dated March 18, 2025, regarding the proposed acquisition of Monjin Interviews Pvt. Ltd.
The company intends to continue evaluating and reviewing alternative acquisition opportunities.

Key Details

Transaction Status: The non-binding letter of intent for the acquisition of Monjin Interviews Pvt. Ltd. has been mutually terminated by both parties.
Original LOI Date: March 18, 2025.
Future Strategy: Optimind Pharma Corp. is continuing to evaluate and review alternative acquisition opportunities.

Notable Quotes

"The company is continuing to evaluate and review alternative acquisition opportunities."

Read the original news release →

More from Optimind Pharma Corp

Sep 08, 2025 · 15:19

Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk